Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Down Today?

Arrowhead Pharmaceuticals shares fell 15.34% to $49.24, marking a significant decline for the biotechnology firm. The primary driver of the move was the presentation of new clinical data at the American Heart Association 2026 Scientific Sessions, where results for the company's RNAi therapies were disclosed.

What Happened

Arrowhead Pharmaceuticals announced that its investigational drug plozasiran achieved a 78% reduction in acute pancreatitis events compared to placebo. The data also showed sustained triglyceride reductions. Additionally, the company presented results for ARO-DIMER-PA, which demonstrated the ability to lower LDL cholesterol and triglycerides. Despite these promising clinical outcomes, the stock experienced a sharp drop, with intraday declines reaching as much as 17.7% during the session. The company also announced its participation in upcoming investor conferences, signaling continued engagement with the market.

What The Data Shows

The stock printed 16 fresh 52-week lows on November 9, 2026, highlighting a recent trend of downward pressure. The 52-week range for ARWR stands between $37.06 and $95.49. Fundamentals indicate a market capitalization of $8.2 billion, with the company remaining unprofitable as trailing twelve-month earnings per share stand at negative $2.28. Revenue grew 16.8% over the trailing twelve months, but the net margin is negative 47.8%. The stock has a beta of 1.37, suggesting higher volatility relative to the broader market. Over the last eight sessions, the stock moved down 3.4% from $60.21 to $58.16. Recent insider activity includes two sales totaling $1.2 million by directors Olukotun Adeoye Y and Perry Michael S in August 2026, with no buys recorded in the last 90 days.

What To Watch

Investors will monitor the company's upcoming participation in investor conferences for further strategic updates. The market will also assess how the new clinical data for plozasiran and ARO-DIMER-PA influences future valuation metrics, particularly given the current unprofitable status and recent 52-week lows.